ORTEXORTEX News
Tracking ZTO? Get live short interest, options flow, and signals on ORTEX.Sign up free →
ZT
Earnings PreviewZTO

ZTO Express Heads Into Q1 Print With JPMorgan's Upgraded Target in Sight

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 12 May 2026, 04:00

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit
ORTEX chart of ZTO Express (Cayman) Inc. (ZTO) share price and short interest (% of free float), three months to May 8, 2026
ORTEX data as of 12 May 2026, 04:00

ZTO Express heads into its May 15 Q1 earnings report riding a quiet but genuine stock recovery — up 20% year-to-date and within reach of a price target that was just raised above where the stock now trades.

The most actionable analyst signal here is a recent JPMorgan move. In April, JPMorgan raised its ZTO target from $25 to $29, keeping an Overweight rating — a vote of confidence that comes at a moment when the stock at $25.01 is essentially at the prior target and still 16% below the new one. That upgrade anchors a broadly constructive Street view: analyst consensus implies roughly 15.6% return potential from current levels. B of A Securities holds a Neutral rating. With EPS surprise ranking in the 99th percentile of the ORTEX universe and forward EPS momentum in the 78th percentile over 90 days, the fundamental track record has given bulls reason to lean in — the company has almost never missed estimates. Annual revenue runs at $8.2 billion with net income near $1.5 billion. At 7.3x EV/EBITDA and a 12.4x trailing P/E, valuation remains undemanding for a dominant Chinese logistics franchise.

The short positioning landscape adds little drama to the setup. Short sellers pulled back sharply over the past month — shares short dropped nearly 18% — bringing the borrow pool demand down considerably. Cost to borrow is minimal at 0.54%, and availability is ample, with utilization running around 24%, well below its 52-week peak of 69%. That means the borrow market is relaxed: no squeeze pressure, no elevated cost for bears. The ORTEX short score of 54.5, essentially neutral, reflects this equilibrium. Short interest simply isn't telling a contrarian story here in either direction.

Options positioning carries the more interesting pre-earnings tension. The put/call ratio has climbed to 2.66, near its 52-week high of 2.68 and well above its 20-day average of 2.62 — though the z-score of 0.4 keeps this shy of outright alarm. What the elevated PCR does signal is that the options market has accumulated a significant protective overhang relative to bullish call exposure. That structure can be read as hedging by long holders rather than pure directional bearishness, particularly given the stock's gentle uptrend. Founder and Chairman/CEO Meisong Lai holds 27.7% of shares, while Alibaba holds a further 8.8% — concentrated ownership that limits float and keeps institutional flows meaningful when they move. JPMorgan Chase as an institution built a position worth roughly $10.9 million as of late April.

Thursday's print is therefore less about whether ZTO can beat — it almost always does — and more about whether management's volume guidance for the back half of 2026 justifies the stock holding above the previous $25 consensus target and working toward the newly raised $29 level.

Against its own history

This week's change in short interest is 2.0 standard deviations below the company's typical weekly move over the past year.

Against its peers

Shares moved +0.1% over the past week against a median of -1.7% for its closest peers.

Stocks in this article

See the live data behind this article on ORTEX.

Open ZTO on ORTEX →

How this article was generated

Generated
12 May 2026, 04:04
Data as of
12 May 2026, 04:00
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signals

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.